

WEST Search History

DATE: Monday, March 10, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L5	L2 and ascorb\$	2	L5
L4	L2 and (antioixant\$)	0	L4
L3	L1 and (antioxidant\$)	2	L3
L2	L1 and Topical\$	8	L2
L1	\$arginine same (genital\$ or penis)	27	L1

END OF SEARCH HISTORY

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 8 of 8 returned.**☐ 1. Document ID: US 6458841 B2

L2: Entry 1 of 8

File: USPT

Oct 1, 2002

US-PAT-NO: 6458841

DOCUMENT-IDENTIFIER: US 6458841 B2

TITLE: Topical and oral delivery of arginine to cause beneficial effects

DATE-ISSUED: October 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fossel; Eric T.	South Hero	VT		

US-CL-CURRENT: 514/565; 424/401, 424/439, 424/450

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC
Draw Desc	Image										

☐ 2. Document ID: US 6436997 B1

L2: Entry 2 of 8

File: USPT

Aug 20, 2002

US-PAT-NO: 6436997

DOCUMENT-IDENTIFIER: US 6436997 B1

TITLE: Endogenous nitric oxide synthesis under conditions of low oxygen tension

DATE-ISSUED: August 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Tejada; Inigo Saenz	Madrid			ES

US-CL-CURRENT: 514/565

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC
Draw Desc	Image										

☐ 3. Document ID: US 6387890 B1

L2: Entry 3 of 8

File: USPT

May 14, 2002

US-PAT-NO: 6387890

DOCUMENT-IDENTIFIER: US 6387890 B1

TITLE: Compositions and methods for inhibiting arginase activity

DATE-ISSUED: May 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Christianson; David	Media	PA		
Baggio; Ricky	Waltham	MA		
Elbaum; Daniel	Newton	MA		

US-CL-CURRENT: 514/64; 562/7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 4. Document ID: US 6362225 B1

L2: Entry 4 of 8

File: USPT

Mar 26, 2002

US-PAT-NO: 6362225

DOCUMENT-IDENTIFIER: US 6362225 B1

TITLE: Target therapies for treating common viral infections

DATE-ISSUED: March 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Andreaskos; George	Honesdale	PA	18431	

US-CL-CURRENT: 514/561; 424/43, 424/46, 424/464, 514/958, 514/959

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 5. Document ID: US 6277884 B1

L2: Entry 5 of 8

File: USPT

Aug 21, 2001

US-PAT-NO: 6277884

DOCUMENT-IDENTIFIER: US 6277884 B1

TITLE: Treatment of sexual dysfunction with N-hydroxyguanidine compounds

DATE-ISSUED: August 21, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Tejada; Inigo Saenz	Madrid			ES

US-CL-CURRENT: 514/565

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 6. Document ID: US 6207713 B1

L2: Entry 6 of 8

File: USPT

Mar 27, 2001

US-PAT-NO: 6207713

DOCUMENT-IDENTIFIER: US 6207713 B1

TITLE: Topical and oral delivery of arginine to cause beneficial effects

DATE-ISSUED: March 27, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fossel; Eric T.	S. Hero	VT	05486	

US-CL-CURRENT: 514/565; 424/401, 424/439, 424/450

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 7. Document ID: US 5594032 A

L2: Entry 7 of 8

File: USPT

Jan 14, 1997

US-PAT-NO: 5594032

DOCUMENT-IDENTIFIER: US 5594032 A

TITLE: Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA

DATE-ISSUED: January 14, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gonzalez-Cadavid; Nestor F.	Pasadena	CA	91107	
Rajfer; Jacob	Rolling Hills Estates	CA	90274	

US-CL-CURRENT: 514/645; 435/195, 435/212, 435/226, 435/228, 514/740, 530/395

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 8. Document ID: US 5439938 A

L2: Entry 8 of 8

File: USPT

Aug 8, 1995

US-PAT-NO: 5439938

DOCUMENT-IDENTIFIER: US 5439938 A

TITLE: Treatments for male sexual dysfunction

DATE-ISSUED: August 8, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Snyder; Solomon H.	Baltimore	MD		
Burnett; Arthur L.	Baltimore	MD		
Lowenstein; Charles J.	Tacoma Park	MD		
Bredt; David S.	Baltimore	MD		
Chang; Thomas S. K.	Baltimore	MD		

US-CL-CURRENT: 514/565

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KM/C
Draw Desc	Image									

Generate Collection

Print

Terms

Documents

L1 and Topical\$

8

Display Format:

-

Change Format

[Previous Page](#)

[Next Page](#)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 2 of 2 returned.**☐ 1. Document ID: US 6387890 B1

L3: Entry 1 of 2

File: USPT

May 14, 2002

US-PAT-NO: 6387890

DOCUMENT-IDENTIFIER: US 6387890 B1

TITLE: Compositions and methods for inhibiting arginase activity

DATE-ISSUED: May 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Christianson; David	Media	PA		
Baggio; Ricky	Waltham	MA		
Elbaum; Daniel	Newton	MA		

US-CL-CURRENT: 514/64; 562/7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[KMIC](#)☐ 2. Document ID: US 6368640 B1

L3: Entry 2 of 2

File: USPT

Apr 9, 2002

US-PAT-NO: 6368640

DOCUMENT-IDENTIFIER: US 6368640 B1

TITLE: Method and composition for improving sexual fitness

DATE-ISSUED: April 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wuh; Hank C. K.	Los Altos	CA		
Trant; Aileen S.	Mountain View	CA		
Kwock; Denny W.	Honolulu	HI		

US-CL-CURRENT: 424/728; 424/725, 424/752

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[KMIC](#)

[Generate Collection](#)[Print](#)

Terms	Documents
L1 and (antioxidant\$)	2

Display Format:

-

[Change Format](#)[Previous Page](#)[Next Page](#)

WEST

Generate Collection

Print

L5: Entry 1 of 2

File: USPT

May 14, 2002

DOCUMENT-IDENTIFIER: US 6387890 B1

TITLE: Compositions and methods for inhibiting arginase activity

Detailed Description Text (37):

Pharmaceutical compositions that are useful in the methods of the invention can be prepared, packaged, or sold in formulations suitable for oral, rectal, vaginal, parenteral, topical, pulmonary, intranasal, buccal, ophthalmic, or another route of administration. Other contemplated formulations include projected nanoparticles, liposomal preparations, resealed erythrocytes containing the active ingredient, and immunologically-based formulations.

Detailed Description Text (49):

Liquid suspensions can be prepared using conventional methods to achieve suspension of the active ingredient in an aqueous or oily vehicle. Aqueous vehicles include, for example, water and isotonic saline. Oily vehicles include, for example, almond oil, oily esters, ethyl alcohol, vegetable oils such as arachis, olive, sesame, or coconut oil, fractionated vegetable oils, and mineral oils such as liquid paraffin. Liquid suspensions can further comprise one or more additional ingredients including, but not limited to, suspending agents, dispersing or wetting agents, emulsifying agents, demulcents, preservatives, buffers, salts, flavorings, coloring agents, and sweetening agents. Oily suspensions can further comprise a thickening agent. Known suspending agents include, but are not limited to, sorbitol syrup, hydrogenated edible fats, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, and cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose. Known dispersing or wetting agents include, but are not limited to, naturally-occurring phosphatides such as lecithin, condensation products of an alkylene oxide with a fatty acid, with a long chain aliphatic alcohol, with a partial ester derived from a fatty acid and a hexitol, or with a partial ester derived from a fatty acid and a hexitol anhydride (e.g. polyoxyethylene stearate, heptadecaethyleneoxycetanol, polyoxyethylene sorbitol monooleate, and polyoxyethylene sorbitan monooleate, respectively). Known emulsifying agents include, but are not limited to, lecithin and acacia. Known preservatives include, but are not limited to, methyl, ethyl, or n-propyl-para-hydroxybenzoates, ascorbic acid, and sorbic acid. Known sweetening agents include, for example, glycerol, propylene glycol, sorbitol, sucrose, and saccharin. Known thickening agents for oily suspensions include, for example, beeswax, hard paraffin, and cetyl alcohol.

Detailed Description Text (62):

Formulations suitable for topical administration include, but are not limited to, liquid or semi-liquid preparations such as liniments, lotions, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes, and solutions or suspensions. Topically-administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of the active ingredient can be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration can further comprise one or more of the additional ingredients described herein.

Detailed Description Text (244):

The crystal structure of the complex formed between the bi-nuclear manganese metalloenzyme arginase and 2(S)-amino-6-boronohexanoic acid (AB HA) has been determined at 1.7 angstrom resolution from a crystal perfectly twinned by hemihedry. ABHA binds as the tetrahedral boronate anion, with one hydroxyl oxygen symmetrically

bridging the bi-nuclear manganese cluster and a second hydroxyl oxygen coordinating to Mn^{sup.2+.sub.A}. This binding mode mimics the transition state of a metal-activated hydroxide mechanism. This transition state structure differs from that occurring in NO biosynthesis, thereby explaining why AHA does not inhibit NO synthase. Arginase activity is present in the penis. ABHA causes significant enhancement of non-adrenergic, non-cholinergic (NANC) nerve-mediated relaxation of penile corpus cavernosum smooth muscle, indicating that arginase inhibition sustains L-arginine concentration at a sufficiently high level in the muscle that NO synthase is active. Thus, the experiments presented in this Example demonstrate that human penile arginase is a target for therapeutic intervention in treatment of erectile dysfunction.

Detailed Description Text (273):

Bioavailability of substrate L-arginine for NO biosynthesis can be a function of dietary intake. For instance, dietary supplementation with L-arginine in an animal model resulted in increased levels of NO synthase activity and enhanced erectile function without changing NO synthase expression, suggesting that L-arginine concentrations in the penis can be a substrate-limiting factor for NO synthase activity (see Moody et al., 1997, J. Urol. 158:942-947). Furthermore, long-term oral administration of L-arginine in patients with interstitial cystitis increased NO-related enzymes and metabolites (Wheeler et al., 1997, J. Urol. 158:2045-2050). Oral administration of 2,800 milligrams per day L-arginine improved erections in 40% of impotent but otherwise healthy patients in a pilot study (Zorgniotti et al., 1994, J. Impotence Res. 6:33-35).

Detailed Description Text (274):

Although the connection between L-arginine bioavailability and NO biosynthesis is complex, enhancement of NANC nerve-mediated smooth muscle tone effected by ABHA indicates that arginase has a role in modulating L-arginine bioavailability for NO biosynthesis in the penis. These experiments demonstrate that the activity of human penile arginase can be inhibited using ABHA or another arginase inhibitor described herein in order to alleviate or inhibit erectile dysfunction.

Arginine

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 30 of 32 returned.**☐ 1. Document ID: US 6489308 B1

L3: Entry 1 of 32

File: USPT

Dec 3, 2002

US-PAT-NO: 6489308

DOCUMENT-IDENTIFIER: US 6489308 B1

TITLE: Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions

DATE-ISSUED: December 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shapiro; Leland	Denver	CO		

US-CL-CURRENT: [514/45](#); [514/423](#), [514/454](#), [514/613](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

☐ 2. Document ID: US 6482854 B1

L3: Entry 2 of 32

File: USPT

Nov 19, 2002

US-PAT-NO: 6482854

DOCUMENT-IDENTIFIER: US 6482854 B1

TITLE: Glaucoma treatment

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lipton; Stuart A.	Newton	MA		
Dreyer; Evan B.	Newton	MA		

US-CL-CURRENT: [514/523](#); [514/912](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

☐ 3. Document ID: US 6423687 B1

L3: Entry 3 of 32

File: USPT

Jul 23, 2002

US-PAT-NO: 6423687

DOCUMENT-IDENTIFIER: US 6423687 B1

TITLE: Pharmaceutical preparations of glutathione and methods of administration thereof

DATE-ISSUED: July 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demopolos; Harry B.	Scarsdale	NY		
Seligman; Myron L.	Pleasantville	NY		

US-CL-CURRENT: 514/18; 514/21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 4. Document ID: US 6417205 B1

L3: Entry 4 of 32

File: USPT

Jul 9, 2002

US-PAT-NO: 6417205

DOCUMENT-IDENTIFIER: US 6417205 B1

TITLE: Nicotine in therapeutic angiogenesis and vasculogenesis

DATE-ISSUED: July 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooke; John	Palo Alto	CA		
Jang; James	San Bruno	CA		
Tsao; Phillip	San Jose	CA		
Heeschen; Christopher	Menlo Park	CA		

US-CL-CURRENT: 514/343; 424/751

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC
Draw Desc	Image										

☐ 5. Document ID: US 6380261 B1

L3: Entry 5 of 32

File: USPT

Apr 30, 2002

US-PAT-NO: 6380261

DOCUMENT-IDENTIFIER: US 6380261 B1

TITLE: Calcium blockers to treat proliferative vitreoretinopathy

DATE-ISSUED: April 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dreyer; Evan B.	Penn Valley	PA		

US-CL-CURRENT: 514/656; 514/912

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 6. Document ID: US 6379882 B1

L3: Entry 6 of 32

File: USPT

Apr 30, 2002

US-PAT-NO: 6379882

DOCUMENT-IDENTIFIER: US 6379882 B1

TITLE: Method for selecting compounds for treating ischemia-related cellular damage

DATE-ISSUED: April 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bitler; Catherine M.	Menlo Park	CA		
Meyer-Franke; Anke	Menlo Park	CA		
Wood; Paul	Menlo Park	CA		

US-CL-CURRENT: 435/4; 435/6, 435/7.8, 514/12, 514/13, 514/14, 514/21, 514/29, 514/3, 514/35, 514/36, 514/37, 514/38, 514/46, 514/49, 530/399

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 7. Document ID: US 6350467 B1

L3: Entry 7 of 32

File: USPT

Feb 26, 2002

US-PAT-NO: 6350467

DOCUMENT-IDENTIFIER: US 6350467 B1

TITLE: Pharmaceutical preparations of glutathione and methods of administration thereof

DATE-ISSUED: February 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demopoulos; Harry B.	Scarsdale	NY		
Seligman; Myron L.	Pleasantville	NY		

US-CL-CURRENT: 424/456; 424/422, 424/434, 424/451, 424/464, 424/484, 514/18, 514/21, 514/824, 514/851, 514/866, 514/879, 514/885, 514/894, 514/912, 514/913, 514/934, 514/944, 514/962, 514/970

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 8. Document ID: US 6346519 B1

L3: Entry 8 of 32

File: USPT

Feb 12, 2002

US-PAT-NO: 6346519

DOCUMENT-IDENTIFIER: US 6346519 B1

TITLE: Method and composition for treating arthritis

DATE-ISSUED: February 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Petrus; Edward J.	Austin	TX		

US-CL-CURRENT: 514/62; 514/61, 514/825, 514/885

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 9. Document ID: US 6267957 B1

L3: Entry 9 of 32

File: USPT

Jul 31, 2001

US-PAT-NO: 6267957

DOCUMENT-IDENTIFIER: US 6267957 B1

TITLE: Attaching agents to tissue with transglutaminase and a transglutaminase substrate

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Green; Howard	Brookline	MA	02146	
Corey; George D.	Newton	MA	02165	
Compton; Bruce J.	Lexington	MA	02173	
Dijan; Philippe	75015 Paris			FR

US-CL-CURRENT: 424/94.5; 424/401, 424/59, 424/94.63, 435/16, 435/177, 435/193, 514/2, 530/402, 530/812

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 10. Document ID: US 6242010 B1

L3: Entry 10 of 32

File: USPT

Jun 5, 2001

US-PAT-NO: 6242010

DOCUMENT-IDENTIFIER: US 6242010 B1

TITLE: Synergistic antioxidant compositions in management of hemorrhoids and other ano-rectal inflammatory conditions

DATE-ISSUED: June 5, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hersh; Theodore	Atlanta	GA		

US-CL-CURRENT: 424/702; 424/400, 424/729, 424/94.1, 424/DIG.15, 514/562, 514/882, 514/937, 514/944, 514/966, 514/969

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 11. Document ID: US 6204248 B1

L3: Entry 11 of 32

File: USPT

Mar 20, 2001

US-PAT-NO: 6204248

DOCUMENT-IDENTIFIER: US 6204248 B1

TITLE: Pharmaceutical preparations of glutathione and methods of administration thereof

DATE-ISSUED: March 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demopoulos; Harry B.	Scarsdale	NY		
Seligman; Myron L.	Fairfield	CT		

US-CL-CURRENT: 514/21; 514/18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 12. Document ID: US 6159500 A

L3: Entry 12 of 32

File: USPT

Dec 12, 2000

US-PAT-NO: 6159500

DOCUMENT-IDENTIFIER: US 6159500 A

TITLE: Pharmaceutical preparations of glutathione and methods of administration thereof

DATE-ISSUED: December 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Demopoulos; Harry B.	Scarsdale	NY		
Seligman; Myron L.	Pleasantville	NY		

US-CL-CURRENT: 424/456; 424/451, 424/452, 424/484, 514/18, 514/474, 514/824, 514/851,
514/866, 514/879, 514/894, 514/912 , 514/913, 514/931, 514/934, 514/970

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 13. Document ID: US 6139847 A

L3: Entry 13 of 32

File: USPT

Oct 31, 2000

US-PAT-NO: 6139847

DOCUMENT-IDENTIFIER: US 6139847 A

TITLE: Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis

DATE-ISSUED: October 31, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chobanian; Aram	Natick	MA		
Brecher; Peter	West Newton	MA		

US-CL-CURRENT: 424/400; 514/310

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 14. Document ID: US 6127356 A

L3: Entry 14 of 32

File: USPT

Oct 3, 2000

US-PAT-NO: 6127356

DOCUMENT-IDENTIFIER: US 6127356 A

TITLE: Oxidant scavengers

DATE-ISSUED: October 3, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Crapo; James D.	Durham	NC		
Fridovich; Irwin	Durham	NC		
Oury; Tim	Durham	NC		
Day; Brian J.	Durham	NC		
Folz; Rodney J.	Durham	NC		
Freeman; Bruce A.	Birmingham	AL		
Trova; Michael P.	Schenectady	NY		
Batinic-Haberle; Ines	Durham	NC		

US-CL-CURRENT: [514/185](#); [252/399](#), [252/400.23](#), [435/189](#), [435/252.3](#), [435/320.1](#), [540/145](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMC

☐ 15. Document ID: US 6080877 A

L3: Entry 15 of 32

File: USPT

Jun 27, 2000

US-PAT-NO: 6080877

DOCUMENT-IDENTIFIER: US 6080877 A

TITLE: Taxanes

DATE-ISSUED: June 27, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Swindell; Charles S.	Merion	PA		
Shashoua; Victor E.	Brookline	MA		
Bradley; Matthews O.	Laytonsville	MD		
Webb; Nigel L.	Bryn Mawr	PA		

US-CL-CURRENT: [549/510](#); [549/511](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMC

☐ 16. Document ID: US 6071962 A

L3: Entry 16 of 32

File: USPT

Jun 6, 2000

US-PAT-NO: 6071962

DOCUMENT-IDENTIFIER: US 6071962 A

TITLE: Oxa acids and related compounds for treating skin conditions

DATE-ISSUED: June 6, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ptchelintsev; Dmitri	Mahwah	NJ		
Scancarella; Neil D.	Wyckoff	NJ		
Kalafsky; Robert	Ogdensburg	NJ		

US-CL-CURRENT: [514/558](#); [514/513](#), [514/559](#), [514/560](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMC

☐ 17. Document ID: US 6048886 A

L3: Entry 17 of 32

File: USPT

Apr 11, 2000

US-PAT-NO: 6048886

DOCUMENT-IDENTIFIER: US 6048886 A

TITLE: Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin

DATE-ISSUED: April 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Neigut; Stanley	Plymouth Meeting	PA	19462	

US-CL-CURRENT: 514/412

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 18. Document ID: US 6013646 A

L3: Entry 18 of 32

File: USPT

Jan 11, 2000

US-PAT-NO: 6013646

DOCUMENT-IDENTIFIER: US 6013646 A

TITLE: Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

DATE-ISSUED: January 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roder; Hanno	Ratingen			DE
Lowinger; Timothy B.	Nishinomiya			JP
Brittelli; David R.	Branford	CT		
VanZandt; Michael C.	Guilford	CT		

US-CL-CURRENT: 514/219; 540/556

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 19. Document ID: US 6004798 A

L3: Entry 19 of 32

File: USPT

Dec 21, 1999

US-PAT-NO: 6004798

DOCUMENT-IDENTIFIER: US 6004798 A

TITLE: Retroviral envelopes having modified hypervariable polyproline regions

DATE-ISSUED: December 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Anderson; W. French	San Marino	CA		
Wu; Bonnie Weimin	Pasadena	CA		

US-CL-CURRENT: 435/235.1; 435/320.1, 536/23.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWMC
Draw Desc	Image									

☐ 20. Document ID: US 5994339 A

L3: Entry 20 of 32

File: USPT

Nov 30, 1999

US-PAT-NO: 5994339

DOCUMENT-IDENTIFIER: US 5994339 A

TITLE: Oxidant scavengers

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Crapo; James D.	Durham	NC		
Fridovich; Irwin	Durham	NC		
Oury; Tim	Durham	NC		
Day; Brian J.	Durham	NC		
Folz; Rodney J.	Durham	NC		
Freeman; Bruce A.	Birmingham	AL		

US-CL-CURRENT: 514/185; 252/399, 252/400.23, 435/189, 435/252.3, 435/320.1, 540/145

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWMC
Draw Desc	Image									

☐ 21. Document ID: US 5922773 A

L3: Entry 21 of 32

File: USPT

Jul 13, 1999

US-PAT-NO: 5922773

DOCUMENT-IDENTIFIER: US 5922773 A

TITLE: Glaucoma treatment

DATE-ISSUED: July 13, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lipton; Stuart A.	Newton	MA		
Dreyer; Evan B.	Newton	MA		

US-CL-CURRENT: 514/649; 514/912, 514/913

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 22. Document ID: US 5922346 A

L3: Entry 22 of 32

File: USPT

Jul 13, 1999

US-PAT-NO: 5922346

DOCUMENT-IDENTIFIER: US 5922346 A

TITLE: Antioxidant preparation

DATE-ISSUED: July 13, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hersh; Theodore	Atlanta	GA		

US-CL-CURRENT: 424/439; 424/440, 424/441, 424/464, 424/702, 514/2, 514/904

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 23. Document ID: US 5919815 A

L3: Entry 23 of 32

File: USPT

Jul 6, 1999

US-PAT-NO: 5919815

DOCUMENT-IDENTIFIER: US 5919815 A

TITLE: Taxane compounds and compositions

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bradley; Matthews O.	Laytonville	MD		
Shashoua; Victor E.	Brookline	MA		
Swindell; Charles S.	Merion	PA		
Webb; Nigel L.	Bryn Mawr	PA		

US-CL-CURRENT: 514/449; 549/510

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 24. Document ID: US 5910316 A

L3: Entry 24 of 32

File: USPT

Jun 8, 1999

US-PAT-NO: 5910316

DOCUMENT-IDENTIFIER: US 5910316 A

TITLE: Use of nitric oxide-releasing agents to treat impotency

DATE-ISSUED: June 8, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Keefer; Larry K.	Bethesda	MD		
Saavedra; Joseph E.	Thurmont	MD		
Doherty; Paul C.	Cupertino	CA		
Hanamoto; Mark S.	Belmont	CA		
Place; Virgil A.	Kawaihae	HI		

US-CL-CURRENT: 424/433; 514/963, 600/38

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 25. Document ID: US 5906811 A

L3: Entry 25 of 32

File: USPT

May 25, 1999

US-PAT-NO: 5906811

DOCUMENT-IDENTIFIER: US 5906811 A

TITLE: Intra-oral antioxidant preparations

DATE-ISSUED: May 25, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hersh; Theodore	Atlanta	GA		

US-CL-CURRENT: 424/54; 424/49, 604/58

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 26. Document ID: US 5847003 A

L3: Entry 26 of 32

File: USPT

Dec 8, 1998

US-PAT-NO: 5847003

DOCUMENT-IDENTIFIER: US 5847003 A

TITLE: Oxa acids and related compounds for treating skin conditions

DATE-ISSUED: December 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ptchelintsev; Dmitri	Mahwah	NJ		
Scancarella; Neil	Wyckoff	NJ		
Kalafsky; Robert	Ogdensburg	NJ		

US-CL-CURRENT: 514/532; 514/546, 514/549, 514/558, 514/559, 514/560

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 27. Document ID: US 5834513 A

L3: Entry 27 of 32

File: USPT

Nov 10, 1998

US-PAT-NO: 5834513

DOCUMENT-IDENTIFIER: US 5834513 A

TITLE: Oxa diacids and related compounds for treating skin conditions

DATE-ISSUED: November 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ptchelintsev; Dmitri	Mahwah	NJ		
Scancarella; Neil	Wyckoff	NJ		
Kalafsky; Robert	Ogdensburg	NJ		

US-CL-CURRENT: 514/561; 514/564, 514/566, 514/574

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 28. Document ID: US 5827886 A

L3: Entry 28 of 32

File: USPT

Oct 27, 1998

US-PAT-NO: 5827886

DOCUMENT-IDENTIFIER: US 5827886 A

TITLE: Composition for relief of arthritis-induced symptoms

DATE-ISSUED: October 27, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hersh; Theodore	Atlanta	GA		

US-CL-CURRENT: 514/562; 424/702, 514/162, 514/165, 514/171, 514/474, 514/561, 514/627

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 29. Document ID: US 5795909 A

L3: Entry 29 of 32

File: USPT

Aug 18, 1998

US-PAT-NO: 5795909

DOCUMENT-IDENTIFIER: US 5795909 A

TITLE: DHA-pharmaceutical agent conjugates of taxanes

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shashoua; Victor E.	Brookline	MA		
Swindell; Charles S.	Merion	PA		
Webb; Nigel L.	Bryn Mawr	PA		
Bradley; Matthews O.	Laytonsville	MD		

US-CL-CURRENT: 514/449; 514/549

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

☐ 30. Document ID: US 5691423 A

L3: Entry 30 of 32

File: USPT

Nov 25, 1997

US-PAT-NO: 5691423

DOCUMENT-IDENTIFIER: US 5691423 A

TITLE: Polysaccharide-bound nitric oxide-nucleophile adducts

DATE-ISSUED: November 25, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Smith; Daniel J.	Stow	OH		
Chakravarthy; Debashish	Garrettsville	OH		
Keefer; Larry K.	Bethesda	MD		

US-CL-CURRENT: 525/377; 424/499, 424/78.17, 536/18.7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KMIC

Generate Collection

Print

Terms	Documents
L2 and arginine	32

Display Format:

[Previous Page](#) [Next Page](#)

WEST

Generate Collection

Print

L3: Entry 4 of 32

File: USPT

Jul 9, 2002

DOCUMENT-IDENTIFIER: US 6417205 B1

TITLE: Nicotine in therapeutic angiogenesis and vasculogenesis

Detailed Description Text (29):

Formulations suitable for topical, transcutaneous, and transdermal administration, e.g., to administer the nicotine receptor agonist directly to a wound, may be similarly prepared through use of appropriate suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Topical formulations may be also utilized with a means to provide continuous administration of nicotine or other nicotine receptor agonist by, for example, incorporation into slow-release pellets or controlled-release patches.

Detailed Description Text (30):

The nicotine receptor agonist can also be formulated in a biocompatible gel, which gel can be applied topically (e.g., to facilitate wound healing) or implanted (e.g., to provide for sustained release of nicotine receptor agonist at an internal treatment site). Suitable gels and methods for formulating a desired compound for delivery using the gel are well known in the art (see, e.g., U.S. Pat. Nos. 5,801,033; 5,827,937; 5,700,848; and MATRIGEL.TM.).

Detailed Description Text (37):

In addition to one or more nicotine receptor agonists, the pharmaceutical formulations according to the invention can comprise or be administered in parallel with agents that enhance angiogenesis by enhancing nitric oxide (NO) levels (e.g., by enhancing activity of NO synthase, by enhancing release of NO, etc.) or prostacyclin levels (e.g., by enhancing activity prostacyclin synthase, by enhancing release of prostacyclin, etc.) Exemplary NO level-enhancing agents include, but are not necessarily limited to, L-arginine, L-lysine, and peptides enriched with these amino acids which can serve as substrates for NO; agents that preserve NO activity such as antioxidants (e.g., tocopherol, ascorbic acid, ubiquinone) or antioxidant enzymes (e.g., superoxide dismutase); and agents which can enhance NO synthase activity (e.g., tetrahydrobiopterin, or precursors for tetrahydrobiopterin (e.g., sepiapterin)); and the like. Exemplary prostacyclin level-enhancing agents include, but are not limited to precursors for prostacyclin such as eicosopentanoic acid and docosohexanoic acid; and prostanoids such as prostaglandin E1 and its analogues; and the like.

Detailed Description Text (46):

In other embodiments it may be desirable to deliver the nicotine receptor agonist formulation topically, e.g., for localized delivery, e.g., to facilitate wound healing. Topical application can be accomplished by use of a biocompatible gel, which may be provided in the form of a patch, or by use of a cream, foam, and the like. Several gels, patches, creams, foams, and the like appropriate for application to wounds can be modified for delivery of nicotine receptor agonist formulations according to the invention (see, e.g., U.S. Pat. Nos. 5,853,749; 5,844,013; 5,804,213; 5,770,229; and the like). In general, topical administration is accomplished using a carrier such as a hydrophilic colloid or other material that provides a moist environment. Alternatively, for the purpose of wound healing the nicotine agonist could be supplied, with or without other angiogenic agents in a gel or cream the could be applied to the wound. An example of such an application would be as a sodium carboxymethylcellulose-based topical gel with a low bioburden containing the nicotine agonist and other active ingredients together with

preservatives and stabilizers.

Detailed Description Text (55):

The following dosages assume that nicotine is being administered, or a nicotine receptor agonist with similar potency and efficacy as nicotine. As will be readily apparent to the ordinarily skilled artisan, the dosage is adjusted for nicotine receptor agonists according to their potency and/or efficacy relative to nicotine. If given orally or as an inhalant, the dose may be in the range of about 0.01 mg to 10 mg, given 1 to 20 times daily, and can be up to a total daily dose of about 0.1 mg to 100 mg. If applied topically, for the purpose of a systemic effect, the patch or cream would be designed to provide for systemic delivery of a dose in the range of about 0.01 mg to 10 mg. If the purpose of the topical formulation (e.g., cream) is to provide a local angiogenic effect, the dose would likely be in the range of about 0.001 mg to 1 mg. If injected for the purpose of a systemic effect, the matrix in which the nicotine agonist is administered is designed to provide for a systemic delivery of a dose in the range of about 0.001 mg to 1 mg. If injected for the purpose of a local effect, the matrix is designed to release locally an amount of nicotine agonist in the range of about 0.003 mg to 1 mg.

Detailed Description Text (86):

Under basal conditions (untreated water, vehicle-treated disc), fibrovascular growth into the disc occurred. Vessels could be seen growing into the disc. These vessels were in continuity with the systemic circulation as manifested by the influx of leuconyl dye into the disc vasculature, after systemic administration of the dye. The area of the fibrovascular growth into the disc under basal conditions was somewhat greater than 10 mm.^{sup.2} (FIG. 2). With systemic administration of nicotine, there was a dramatic increase in fibrovascular growth with an area of 35 mm.^{sup.2} (FIG. 2). The effect of nicotine was blocked by the NO synthase inhibitor L, nitro-arginine (LNNA) as well as by indomethacin, indicating that synthesis of both nitric oxide and prostacyclin were required for the angiogenic effect of nicotine.

CLAIMS:

8. The method of claim 1, wherein said administering is topical.

14. The method of claim 13, wherein the agent is selected from the group consisting of a nitric oxide substrate, an antioxidant, and a nitric oxide synthase co-factor.

15. The method of claim 13, wherein the agent is selected from the group consisting of L-arginine, L-lysine, tocopherol, ascorbic acid, ubiquinone, superoxide dismutase, tetrahydrobiopterin, and sepiapterin.

WEST

Print

Jun 8, 1999

TITLE: Use of nitric oxide-releasing agents to treat impotency

The nitric oxide-releasing agents can be administered in a wide variety of forms of delivery means. Any delivery means should adequately protect the integrity of the NO prior to its release and should control the release of the NO at such a rate, in such an amount, and in such a location as to serve as an effective means of treating the impotency. For example, delivery means for local administration or administration for localized release include, but are not limited to, a penile implant, a drug pump, a drug-delivery catheter (pressure-driven, iontophoretic or transurethral), a self-adhering means, a liposome, a microparticle, a microsphere, a bead, a condom, a dermal patch, a disk or other device. The advantages of local administration or localized release include the ability to attain effective concentrations of NO at the target site more quickly, the use of a smaller dose, and the realization of fewer toxic side effects than could occur on systemic administration and release. Delivery means for systemic administration for localized release include, but are not limited to, solutions, suspensions, emulsions, capsules, sachets, tablets, dermal (topical) patches, lozenges, aerosols, liposomes, microparticles, microspheres, beads, prodrugs, tissue-specific antibodies, small peptides that mimic ligand recognition sequences, and sequence-specific oligonucleotides as described above. The polymer, itself, may be structurally sufficient to serve as a form of delivery means. Alternatively, the polymer can be incorporated into or coated onto other matrices, substrates or the like, or can be microencapsulated or the like.

The drug also may be administered topically, transdermally or by any other available and effective means. Transdermal drug administration, as is well known to those skilled in the art, involves the delivery of a pharmaceutical agent via percutaneous passage of the drug into the systemic circulation of the patient. See Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989); Controlled Drug Delivery: Fundamentals and Applications, Robinson and Lee (eds.), Marcel Dekker Inc., (1987); and Transdermal Delivery of Drugs, Vols. 1-3, Kydonieus and Berner (eds.), CRC Press (1987).

Kanner et al., "Nitric Oxide as an Antioxidant," Archives of Biochemistry and Biophysics, 289, 130-136 (1991).

Morikawa et al., "L-Arginine Decreases Infarct Size Caused by Middle Cerebral Arterial Occlusion in SHR," Am. J. Physiol., 263, H1632-H1635 (1992).

WEST

[Generate Collection](#)[Print](#)

Search Results - Record(s) 31 through 32 of 32 returned.

☐ 31. Document ID: US 5645839 A

L3: Entry 31 of 32

File: USPT

Jul 8, 1997

US-PAT-NO: 5645839

DOCUMENT-IDENTIFIER: US 5645839 A

TITLE: Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis

DATE-ISSUED: July 8, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chobanian; Aram	Natick	MA		
Brecher; Peter	West Newton	MA		

US-CL-CURRENT: [424/400](#); [424/43](#), [424/451](#), [424/464](#), [424/474](#), [424/489](#), [514/310](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 32. Document ID: US 5597809 A

L3: Entry 32 of 32

File: USPT

Jan 28, 1997

US-PAT-NO: 5597809

DOCUMENT-IDENTIFIER: US 5597809 A

TITLE: Treatment of optic neuritis

DATE-ISSUED: January 28, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dreyer; Evan B.	Chestnut Hill	MA		

US-CL-CURRENT: [514/34](#); [514/145](#), [514/148](#), [514/224.8](#), [514/231.2](#), [514/233.2](#), [514/256](#), [514/266.4](#), [514/277](#), [514/278](#), [514/299](#), [514/312](#), [514/314](#), [514/317](#), [514/345](#), [514/469](#), [514/492](#), [514/493](#), [514/498](#), [514/501](#), [514/504](#), [514/530](#), [514/601](#), [514/602](#), [514/608](#), [514/613](#), [514/616](#), [514/646](#), [514/647](#), [514/662](#), [514/664](#), [514/665](#), [514/706](#), [514/707](#), [514/724](#), [514/731](#), [514/734](#), [514/744](#), [514/745](#), [514/757](#), [514/759](#), [514/764](#), [514/912](#), [514/913](#), [514/914](#), [514/915](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									